-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 2, the Insight database showed that Hainan Simcere Pharmaceutical’s application for the listing of 4 types of generic drug idoxaban tosylate tablets was accepted (acceptance number: CYHS2101233/4/5) for the treatment of stroke and atrial fibrillation To prevent systemic embolism, it is the first domestic producer of this species.
Idoxaban tosylate was developed by Daiichi Sankyo, and was first marketed in Japan in April 2011 for venous thromboembolism (VTE).
Officially entered China in December 2018 for patients with one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, history of previous stroke or transient ischemic attack (TIA)) Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF).
Public data shows that the global sales of Edoxaban in 2020 will be 16.
On December 28, 2020, the new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" was officially announced.
According to the Insight database, as of now, many companies’ generic drug products have been approved for clinical trials.